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Vaccines represent the most commonly employed immu- 
nologic intervention in medicine today. Indeed, they are 
currently one of the few antigen-specific approaches with 
clearly documented clinical success. Current estimates 
by the Centers for Disease Control indicate that greater 
than 5,000,OOO doses of vaccine against some infectious 
organism are administered yearly in the United States, 
making vaccines the most commonly administered immu- 
notherapeutic. Current vaccines target only a tiny fraction 
of infectious diseases, since prophylaxis against some of 
the most common and deadly infections in the third world 
is limited by expense and ease of distribution. In addition 
to the public health concerns of expense and distribution, 
other features of current vaccines limit their efficacy. While 
most current vaccines typically elicit reasonable antibody 
responses, cellular responses (in particular, major histo- 
compatibility complex [MHC] class l-restricted cytotoxic 
T cells) are generally absent or weak. For many infectious 
diseases, such as tuberculosis and malaria, humoral re- 
sponses have been shown to be of little protective value 
against infection. Another limitation of most current vac- 
cines relates to the limited duration of immunologic mem- 
ory. Ideal vaccines would provide lifelong prophylaxis, a 
goal generally not achieved by current formulations. 
In the last three years, DNAvaccines have burst onto the 
scene as a radically new approach to infectious disease 
prophylaxis. One of the most surprising and important fea- 
tures of DNA immunization is that purified “naked” DNA 
appears to be taken up and expressed by cells in vivo with 
much greater efficiency than would have been predicted 
by the experience with DNA transfection in tissue culture. 
This finding provides the basis for a critical pharmaceutical 
advantage of DNAvaccines: namely, simplicity of prepara- 
tion. In addition, naked DNA can be produced in large 
scale with tremendous purity, allowing for freedom from 
contamination with potentially dangerous agents. The final 
pharmaceutical advantage of DNA is its tremendous sta- 
bility relative to proteins and other biologic polymers, a 
feature likely to be more relevant for the production of 
vaccines than the recreation of dinosaurs. 
From an immunologic perspective, the unique ability of 
DNA to either integrate stably into the genome or be main- 
tained long-term in an episomal form provides the potential 
for long-lived antigen expression. This feature thus has 
implications for the duration of immunologic memory 
achievable with nucleic acid vaccines. Despite the flurry 
of reports documenting the ability of naked DNA vaccines 
to induce both immunologic and protective responses in 
animal models, the mechanism by which DNA injections 
activate the immune system against the encoded antigens 
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remains somewhat mysterious. Nonetheless, given what 
is now understood about pathways of antigen processing 
and the requirements for T cell activation, exposing the 
mechanisms of immune activation by naked DNA may 
reveal some provocative clues to how the immune system 
deals with different forms of antigen. 
Methods of In Vlvo Transduction with Injected DNA 
As is so often the case with active areas of investigation, 
evidence for in vivo transduction by injection of purified 
DNA was observed many decades ago, but remained 
largely unnoticed until its more recent resurrection. As 
early as 1960, Ito (1960) demonstrated the induction of 
papillomas in rabbit skin by injecting phenol-extracted nu- 
cleic acids from the Shope rabbit papilloma virus. Then, 
in 1990, Wolff et al. demonstrated direct gene transfer into 
mouse muscle in vivo with reporter constructs (Wolff et al., 
1990). Using either chloramphenicol acetyl transferase, 
luciferase, or P-galactosidase, they demonstrated that in- 
jection of either purified RNA or DNA could result in ex- 
pression of the appropriate enzyme activity within the skel- 
etal muscle. When 100 pg of purified DNA consisting of 
the reporter gene linked to a Rous Sarcoma Virus LTR 
(RSVL) promoter was injected, episomal plasmid DNA 
could be detected by Southern blot 30 days later and en- 
zyme activity persisted for at least 60 days after injection. 
The stability of this episomal form of DNA is presumably 
due to the low proliferative state of myocytes in vivo. Nu- 
merous subsequent studies have evaluated different pa- 
rameters of in vivo gene transfer, including injection vehi- 
cle, promoter, DNA structure, and route of injection (Davis 
et al., 1993a; Eisenbraun et al., 1993; Fynan et al., 1993b; 
Jiao et al., 1992; Manthorpe et al., 1993; Prigozy et al., 
1993; Wolff et al., 1991). 
Surprisingly, most investigators have found that simple 
saline solutions appear to be quite reasonable carriers, 
often resulting in transfection of between l %-5%of myofi- 
brils in the vicinity of the injection site in the case of intra- 
muscular administration. DNA preparations that are typi- 
cally used to transfect cells in vitro, such as calcium 
phosphate precipitates or liposomal preparations, do not 
appear to enhance the efficiency of in vivo transfer (Man- 
thorpe et al., 1993; Wolff et al., 1990). In fact, most agents 
tested that might theoretically enhance in vivo transfection 
efficiency appear to interfere with gene transfer, at least 
into skeletal muscle. Nonetheless, there are a few reports 
that coinjections of toxic agents intended to cause muscle 
necrosis and repair either prior to or concurrently with in- 
jection of DNA, can increase gene transfer and expression 
(Davis et al., 1993a, 1993b; Vitadello et al., 1994; Wang 
et al., 1993a, 1993b). These include local anesthetics, 
such as bupivicaine, and myotoxins, such as cardiotoxin. 
Different promoters that have been compared for effi- 
ciency of gene expression for in vivo DNA transfer include 
CMV-IE, RSV, SV40, SRa, actin, MCK, a-globin, adenovi- 
rus, and dihydrofolate reductase. While relatively few di- 
rect comparisons have been performed, viral promoters 

with broad cell type specificity such as the CMV and RSV 
promoters appear to generate the most consistently high 
levels of expression of reporter constructs. 
With regard to site of injection, the largest experience 
is with injection into skeletal muscle. Other tissue types 
have also been shown to express gene products after DNA 
injection, including cardiac muscle, liver, and dermis (Ac- 
sadietal., 1991;Maloneetal., 1994; Razetal., 1994).0ne 
of the new technologies that has engendered particular 
interest in intradermal DNA injections is the gene gun. 
The gene gun, an instrument currently not covered under 
the assault weapons ban, takes advantage of the ability 
of ballistically accelerated microscopic gold particles to 
penetrate cell membranes without killing the cell. By mix- 
ing these gold particles with purified DNA in the presence 
of a polycations such as spermadine, the nucleic acid be- 
comes coated onto the gold particles. These DNA-coated 
gold particles are loaded into the gene gun and the end 
is abutted to a shaved area of skin. Discharge of the gene 
gun results in penetration of the dermis between 0.1-5 
mm, depending on the chosen projectile force. This form 
of DNA injection has been shown to transduce cells in 
both the dermis and epidermis (Eisenbraun et al., 1993). 
Generation of Immune Responses by Naked 
DNA Vaccines 
It is now well established that injection of naked DNA 
through any of a number of routes reproducibly induces 
both humoral and cellular immune responses against the 
encoded antigens. The initial report that genetic immuni- 
zation could elicit immune responses measured the induc- 
tion of antibodies against human growth hormone (hGH) 
subsequent to ballistic injection of DNA-coated gold parti- 
cles with a gene gun (Tang et al., 1992). hGH gene con- 
structs under transcription control of either the human 
@actin promoter or CMV promoter induced specific anti- 
hGH antibody responses. The titer of antibodies was 
somewhat variable and strain dependent. In addition, 
clear-cut booster effects of subsequent DNA immuniza- 
tions were observed, akin to what is typically seen with 
recombinant protein immunizations. 
Subsequently, Liu and colleagues demonstrated that 
antigen-specific CTL responses could be induced by intra- 
muscular injection of naked DNA (Montgomery et al., 
1993; Ulmer et al., 1993). They utilized an influenza A 
model to emphasize the advantage of a vaccine strategy 
that could induce CTL responses, as humoral responses 
to influenza A tend to be strain specific and poorly cross 
protective. This is because the major antibody responses 
are directed against the hemaglutinin (HA) antigen, which 
varies significantly among different influenza strains. In 
contrast, epitopes of the influenza nucleoprotein (NP) anti- 
gen, a major target for CTL responses, demonstrate sig- 
nificantly less interstrain variability. Using a plasmid 
Figure 1. Biopsy of Muscle after Injection with Purified DNA Encoding 5Galactosidase 
Purified DNA (100 ug) encoding b-galactosidase under transcriptional control of the CMV-IE promoter was injected into the quadriceps muscle 
of a mouse. The muscle was biopsied 5 days later and stained with bluogal and hematoxylin and eosin. Note the expression of jkgalactosidase 
in large proportion of myofibrils (large arrows) as well as the significant inflammatory infiltrate (small arrows). 
containing the NP gene driven by either an RSV or CMV 
promoter, they demonstrated specific CTL responses 
against the NP 147-155 epitope presented by the H-2Kd 
MHC class I molecule. Importantly, animals immunized 
intramuscularly with NP DNA were protected from intrana- 
sal challenge with 102.5 TCID 50 of an influenza isolate, 
AIHlV66, which arose 34 years after the strain from which 
the vaccinating NP gene was isolated (A/PR/A/34). 
Importantly, CTL responses against NP were found to 
persist at least 13 months subsequent to the intramuscular 
DNA injection (Yankauckas et al., 1993). These studies, 
as well as analogous findings in other animal models of 
infectious disease, suggested that naked DNA immuniza- 
tion could produce long-term humoral and cellular immune 
responses qualitatively similar to live attenuated vaccines 
but without the safety hazards of inoculation of live virus. 
Other infectious disease models in which successful im- 
munization and at least partial protection against viral chal- 
lenge have been observed include HIV (using the gp120 
or gp160 genes), bovine herpes virus (GIV gene), rabies 
virus (surface glycoprotein gene), and hepatitis B virus 
(hepatitis B surface antigen) (Cox et al., 1993; Davis et 
al., 1993b; Wang et al., 1993a, 1993b; Xiang et al., 1994). 
In addition to the nucleoprotein gene, DNA vaccinations 
with other influenza genes including HA and matrix protein 
have likewise demonstrated protective responses (Fynan 
et al., 1993a; Montgomery et al., 1993; Robinson et al., 
1993). In essentially all cases, significant titersof neutraliz- 
ing antibody are induced and, in the case of rabies virus 
and HIV, CTL responses were also documented. 
Despite the rapidly expanding volume of reports docu- 
menting successful immunization with naked DNA vac- 
cines, there has yet to be a direct systematic comparison 
of the relative potency of DNA vaccines versus other live 
attenuated viral or recombinant protein plus adjuvant vac- 
cines in standardized animal models. One report did com- 
pare the relative efficacies of naked DNA injections as a 
function of route of inoculation. Using either the HA sub- 
type 1 (Hl) protein in a mouse model of adapted influenza 
virus or the HA subtype 7 (H7) gene in a chicken model 
of influenza, six routes of inoculation (intravenous, intra- 
peritoneal, intranasal, intramuscular, intradermal, subcu- 
taneous) were compared in their ability to induce both anti- 
body responses as well as protective immunity (Fynan et 
al., 1993b). While intramuscular injection of DNA ap- 
peared to generate the best response, intravenous, intra- 
nasal, intradermal, and subcutaneous immunizations also 
induced significant protection. When ballistic inoculation 
of DNA-coated gold particles was evaluated, equivalent 
levels of protection were achieved using 2-3 logs lower 
total DNA dose (0.4 pg) than all of the other forms of inocu- 
lation. In contrast with what might be expected using a 
recombinant protein vaccine, intranasal (mucosal) DNA 
inoculation did not result in enhanced immungolobulin A 
Immunity 
166 
(IgA) titers but rather produced IgG responses similar to 
intramucosal and intravenous injections. Clearly, much 
additional evaluation needs to be done in developing gen- 
eral principles for the quantitative and qualitative aspects 
of DNA immunization. 
Mechanisms of Initiation of Immune Responses 
by DNA Vaccines 
As eluded to above, many of the advantages of DNA vac- 
cines have been proposed to stem from either stable inte- 
gration or extrachromosomal maintenance of the DNA 
within cellsof the injected organ. In thecase of intramuscu- 
lar injections, reporter constructs appear to mark myo- 
cytes specifically as the targets of integration and gene 
expression (Figure 1). The previously proposed mecha- 
nisms for priming of humoral and cellular immune re- 
sponses by DNAvaccines have reflected the distinct path- 
ways of MHC class I and class II antigen processing as 
defined in cell culture. Thus, antibody responses have 
been proposed to occur when antigens encoded by the 
transduced myocyte are released into the circulation ei- 
therviasecretionorviacell death. Theseantigensare then 
taken up by macrophages and B cells, thereby initiating a 
T helper-dependent antibody response. Alternatively, CTL 
priming has been proposed to occur via endogenous pro- 
teosome-dependent processing and presentation of anti- 
gens within the transfected myocyte followed by TAP- 
dependent presentation on the myocyte MHC class I 
molecule (Figure 2A). The stability of the integrated DNA 
sequences would produce an essentially continuous sup 
ply of antigen to drive immune responses indefinitely, thus 
accounting for the long-term persistence of immune re- 
sponses against antigens encoded by the injected DNA. 
If antigen receptor occupancy by peptide-MHC com- 
plexes were the whole story to T cell activation and immu- 
nologic priming, these proposed mechanisms would seem 
the most reasonable. However, they do not account for the 
critical role of costimulatory signals in initiating immune 
responses. Indeed, an increasing body of evidence in the 
self-tolerance field suggests that antigen recognition in 
the absence of appropriate costimulatory signals results 
in immune tolerance (by either ignorance, anergy, or dele- 
tion) rather than activation. Thus, simple release of anti- 
gens by natural processes of cell death do not result in 
induction of immunity. For example, the myocyte cell 
death that invariably occurs after running a marathon does 
not produce autoimmune myocytis. By analogy, it is proba- 
blyoversimplitiic to propose that immune responses against 
antigens encoded by integrated DNA activate and propa- 
gate immune responses when transfected myocytes sim- 
ply die by natural processes. Similarly, the mounting 
evidence for costimulatory requirement in CD8 T cell acti- 
vation implies that direct presentation of endogenously 
synthesized antigens by MHC class I molecules of trans- 
fected myocytes might not be expected to prime CTL pre- 
cursors. 
A critical element to the priming of both humoral and 
cellular immune responses that is usually left out of the 
picture in discussions of naked DNA vaccines is the bone 
marrow-derived antigen-presenting cell (APC). Indeed, al- 
though it has never been systematically studied, sites of 
injected muscle clearly become infiltrated with inflamma- 
tory cells (see Figure 1). As with all other circumstances 
of immunologic activation, it is hard to imagine that bone 
marrow-derived APCs within these inflammatory infil- 
trates do not play an important role in the vaccine effect 
of naked DNA immunizations. In the case of MHC class 
II-restricted CD4+ T cell priming, these APCs would have 
the opportunity to pick up locally released antigens in the 
interstitial spaces and carry them to draining lymph nodes 
where they could be presented to both B cells and T cells. 
With regard to the priming of MHC class l-restricted CD8 
T cells, it may also be worth considering these infiltrating 
APCs as prime suspects in CTL activation (Figure 28). 
Despite the earlier cross-priming experiments of Bevan in 
the 1970s the notion that host-derived APCs could effi- 
ciently ingest released exogenous antigens for processing 
and presentation on MHC class I molecules in vivo had 
been considered improbable, because the defined cellular 
pathways of MHC class I antigen presentation require that 
the antigen be expressed endogenously (Bevan, 1978). 
However, recent experiments designed to determine 
which cell type presents tumor-specific antigens to MHC 
class l-restricted CD8 T cells may be quite analogous to 
the CTL priming that occurs with an in vivo transfected 
myocyte. In both cases, the antigen is initially expressed 
exclusively by a nonprofessional APC. In the case of tumor 
vaccines, Huang et al. (1994) used a model system in 
which a specific antigen (influenza NP) with known MHC 
class I epitopes is expressed by a tumor. Parent Fl chime- 
ras, in which the MHC haplotypes of the bone marrow- 
derived cells either did or did not match the MHC haplotype 
of the tumor cell were vaccinated with NP-expressing tu- 
mors. In all cases, the NP-specific CTL generated were 
specific exclusively for epitopes presented by MHC alleles 
expressed by the bone marrow-derived cells, not the tu- 
mor cell. Thus, the priming of MHC class l-restricted re- 
sponses involved the transfer of that antigen to a host 
bone marrow-derived cell before its presentation to CD8+ 
T cells. Using subsets of macrophages and defined condi- 
tions in vitro, exogenous antigens have recently been 
shown to enter the MHC class I processing pathway (Ko- 
vacsovics-Bankowski and Rock, 1995). 
The most direct evidence implicating bone marrow- 
derived APCs in the priming events of naked DNA vac- 
cines comes from a recent study by Ertl and colleagues. 
Using the murine rabies model, they demonstrated that 
coinjection of naked DNA encoding murine granulocyte- 
macrophage colony-stimulating factor (GM-CSF) with the 
gene encoding rabies glycoprotein enhanced both anti- 
body and cellular responses to the rabies glycoprotein an- 
tigen (Xiang and Ertl, 1995). The enhanced immunologic 
responses correlated with enhanced protection against 
challenge with the rabies virus in vaccinated animals. 
These results appear analogous to findings that tumorvac- 
tines genetically modified to express GM-CSF provide en- 
hanced systemic immunity against challenge with lethal 
doses of unmodified tumor cells injected distant to the 
vaccine site. The proposed mechanism by which para- 
crine GM-CSF elaboration enhances antigen-specific im- 
mune response relates to the ability of this cytokine to 
induce the differentiation of hematopoetic progenitors into 
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Figure 2. Three Possible Models for Priming of MHC Class I-Re- 
stricted CTL Responses by Intramuscular DNA Injections 
(A) Direct presentation by transduced muscle cells. 
(B) Transfer of protein antigens to bone marrow-derived APCs with 
crossover into the MHC class l-processing pathway. 
(C) Uptake of DNA directly into bone marrow-derived APCs infiltrating 
the muscle followed by classical MHC class I processing. 
“professional” APCs. In addition to macrophages, GM- 
CSF has been shown to induce the differentiation and 
maintenance of dendritic cells. This cell type, which is 
2-3 three logs more potent on a per cell basis than macro- 
phages in activating naive T cells in vitro, has been pro- 
posed to be the critical APC in initiating immune responses 
in vivo. Qualitative and quantitative differences in APC 
composition or traffic into different tissue types may, in 
fact, account for the lower amount of DNA necessary for 
intradermal vaccination. In particular, the presence of 
Langerhans cells in the epidermis provides a ready source 
of APCs at the injection site. 
Another model for immunologic priming by naked DNA 
vaccines bears consideration since it has neither been 
ruled in or ruled out. While Sutton’s law dictates that at- 
tention be focused on the myocyte in the case of intramus- 
cular DNA vaccines, it is certainly possible that small 
numbers of infiltrating bone marrow-derived APCs are 
themselves directly transfected (Figure 2C). Because these 
bone marrow-derived cells are motile, while myocytes are 
stationary, they may have fled the scene by the time the 
biopsy is taken, thus giving the appearance that myocytes 
are the only transfected cell. While small in number, such 
transfected bone marrow-derived APCs may ultimately 
be the critical players in priming immune responses in 
draining lymph nodes. 
Now that naked DNA has become established as a clear 
player in the vaccine field, it will be important to dissect 
the mechanisms by which it activates immune responses. 
It is only through these studies that intelligent modifica- 
tions can be introduced to maximize both qualitatively and 
quantitatively its ultimate potency. 
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